Giulia Bellini

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/122541/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Rapid and safe response to lowâ€dose carbamazepine in neonatal epilepsy. Epilepsia, 2016, 57, 2019-2030.	5.1	92
2	lron overload causes osteoporosis in thalassemia major patients through interaction with transient receptor potential vanilloid type 1 (TRPV1) channels. Haematologica, 2014, 99, 1876-1884.	3.5	64
3	The endovanilloid/endocannabinoid system: A new potential target for osteoporosis therapy. Bone, 2011, 48, 997-1007.	2.9	55
4	Cannabinoid Receptor 2 as Antiobesity Target: Inflammation, Fat Storage, and Browning Modulation. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 3469-3478.	3.6	53
5	The Cannabinoid Receptor type 2 Q63R variant increases the risk of celiac disease: Implication for a novel molecular biomarker and future therapeutic intervention. Pharmacological Research, 2012, 66, 88-94.	7.1	52
6	The Endocannabinoid/Endovanilloid System in Bone: From Osteoporosis to Osteosarcoma. International Journal of Molecular Sciences, 2019, 20, 1919.	4.1	50
7	Association Between a Polymorphism in Cannabinoid Receptor 2 and Severe Necroinflammation in Patients With Chronic Hepatitis C. Clinical Gastroenterology and Hepatology, 2014, 12, 334-340.	4.4	44
8	Mifamurtide and TAM-like macrophages: effect on proliferation, migration and differentiation of osteosarcoma cells. Oncotarget, 2020, 11, 687-698.	1.8	35
9	CB2 and TRPV1 receptors oppositely modulate in vitro human osteoblast activity. Pharmacological Research, 2015, 99, 194-201.	7.1	33
10	PKCβII-mediated cross-talk of TRPV1/CB2 modulates the glucocorticoid-induced osteoclast overactivity. Pharmacological Research, 2017, 115, 267-274.	7.1	31
11	The 17-β-oestradiol inhibits osteoclast activity by increasing the cannabinoid CB2 receptor expression. Pharmacological Research, 2013, 68, 7-15.	7.1	29
12	The Endocannabinoid System in Pediatric Inflammatory and Immune Diseases. International Journal of Molecular Sciences, 2019, 20, 5875.	4.1	29
13	Cannabinoid Receptor 2 Functional Variant Contributes to the Risk for Pediatric Inflammatory Bowel Disease. Journal of Clinical Gastroenterology, 2018, 52, e37-e43.	2.2	21
14	Effects of CB2 and TRPV1 receptors' stimulation in pediatric acute T-lymphoblastic leukemia. Oncotarget, 2018, 9, 21244-21258.	1.8	19
15	Anti-proliferative, pro-apoptotic and anti-invasive effect of EC/EV system in human osteosarcoma. Oncotarget, 2017, 8, 54459-54471.	1.8	19
16	The DMT1 IVS4+44C>A polymorphism and the risk of iron deficiency anemia in children with celiac disease. PLoS ONE, 2017, 12, e0185822.	2.5	18
17	The Cannabinoid Receptor 2 Q63R Variant Modulates the Relationship between Childhood Obesity and Age at Menarche. PLoS ONE, 2015, 10, e0140142.	2.5	18
18	The IRGM rs10065172 variant increases the risk for steatosis but not for liver damage progression in Italian obese children. Journal of Hepatology, 2017, 67, 653-655.	3.7	13

GIULIA BELLINI

#	Article	IF	CITATIONS
19	Cannabinoid Receptor 2-63 QQ Variant Is Associated with Persistently Normal Aminotransferase Serum Levels in Chronic Hepatitis C. PLoS ONE, 2014, 9, e99450.	2.5	13
20	The Role of Mifamurtide in Chemotherapy-induced Osteoporosis of Children with Osteosarcoma. Current Cancer Drug Targets, 2017, 17, 650-656.	1.6	12
21	TNF-α effect on human delivery onset by CB1/TRPV1 crosstalk: new insights into endocannabinoid molecular signaling in preterm vs. term labor. Analysis of the EC/EV pathway and predictive biomarkers for early diagnosis of preterm delivery. Minerva Ginecologica, 2019, 71, 359-364.	0.8	11
22	CB2-63 polymorphism and immune-mediated diseases associated with HCV chronic infection. Digestive and Liver Disease, 2016, 48, 1364-1369.	0.9	8